Stifel analysts maintained their Hold rating on Supernus Pharmaceuticals (NASDAQ:SUPN) shares, with a steady price target of $38.00. Trading near its 52-week high with a strong 30% gain over the past ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

Earnings, adjusted for one-time gains ... A live webcast with presentation sl Supernus Pharmaceuticals Inc (SUPN) reports a 32% revenue increase, driven by Qelbree and Gocovri, while advancing ...

Announcing Q3 earnings, Revance revealed year-to-date ... Revance has ~104m shares outstanding (source: Q3 2024 quarterly report / 10Q submission), therefore Crown's original bid valued the ...

As such, the Zacks rating upgrade for Supernus is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. The change in a company's future ...

Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...